Abstract
PurposeWe examined the diagnostic significance, prognostic value, and potential function of AMAP1 in gastric cancer (GC).MethodsComprehensive bioinformatic analysis was conducted to investigate differential expression of AMAP1 mRNA and protein in GC. Meta-analyses were utilized to determine the overall prognostic correlation of AMAP1 mRNA in patients with GC. A panel of vitro assays was applied to assess target microRNA and AMAP1 protein in GC cell lines and tissues, respectively.ResultsAMAP1 mRNA and protein levels were upregulated in GC specimens, compared to matched normal tissues. AMAP1 mRNA exhibited promising results regarding differential diagnosis of GC and normal tissue. Meta-analysis based on the TCGA and GEO databases revealed that high AMAP1 mRNA abundance was associated with poor overall survival (HR = 1.42; 95% CI: 1.06–1.89) and was correlated with reduced progression-free survival (HR = 1.89; 95% CI: 1.51–2.36) in GC patients. Moreover, AMAP1 was negatively correlated with miR-192-3p (r = −0.3843; P < 0.0001). A dual-luciferase assay revealed that miR-192-3p targeted AMAP1. Levels of miR-192-3p were significantly higher in GC tissues and GC cells than in normal tissues and cells. Moreover, AMAP1 silencing resulted in reduced GC proliferation, migration, and invasion.ConclusionAMAP1 is a novel oncogene in GC and is negatively correlated with by miR-192-3p. AMAP1 may act as a diagnostic and prognostic marker of GC.
Highlights
Gastric cancer (GC) is a major global health problem with nearly 800,000 GC-related deaths every year (Bray et al, 2018)
Our results suggested the diagnostic and prognostic value of AMAP1 in patients with GC, and AMAP1 may be a molecular target in GC treatments
We examined for the first time the expression and prognostic value of AMAP1 in GC
Summary
Gastric cancer (GC) is a major global health problem with nearly 800,000 GC-related deaths every year (Bray et al, 2018). As a classical member of the ARF superfamily, AMAP1 exerts various biological effects including regulation of the actin cytoskeleton, integrin adhesion, and tumor invasion and metastasis (Gasilina et al, 2019). Recent studies showed that AMAP1 promotes cell proliferation and tumor invasion in several cancer cells including triple-negative breast cancer (He et al, 2020), ovarian cancer (Zhang et al, 2018), laryngeal squamous cell carcinoma (Li et al, 2014), colorectal cancer (Muller et al, 2010), and prostate cancer (Lin et al, 2008). The role of AMAP1 during GC has never been examined
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call